234.76
7.44 (3.27%)
| Previous Close | 227.32 |
| Volume | 886,982 |
| Price / Earnings (Forward) | 10.29 |
| Price / Sales | 3.40 |
| Price / Book | 3.68 |
| 52 Weeks Range |
| Profit Margin | 11.86% |
| Operating Margin (TTM) | -2.90% |
| Diluted EPS (TTM) | 7.37 |
| Quarterly Revenue Growth (YOY) | -0.50% |
| Quarterly Earnings Growth (YOY) | 103.00% |
| Total Debt/Equity (MRQ) | 129.82% |
| Current Ratio (MRQ) | 3.38 |
| Operating Cash Flow (TTM) | 1.56 B |
| Levered Free Cash Flow (TTM) | 1.50 B |
| Return on Assets (TTM) | 3.99% |
| Return on Equity (TTM) | 12.25% |
AIStockmoo Score
| Value 30% | -2.5 |
| The price implies earnings growth of 22.7% a year; the business can fund about 12.3% a year. info | |
| High debt. Ample short-term liquidity. Positive cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Valuation History info | NA |
| Return on Capital info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | 2.7 |
| Uptrend over the past year. Trading near its 52-week high. info | |
| In an uptrend, but its moving averages have flattened. Volume is heavier on up days. A recent move above resistance has not been confirmed. info | |
| From our AI technical analysis of the chart. info | NA |
| Candle Patterns info | NA |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| Holdings' Sentiment info | NA |
| News Mood info | NA |
| Smart Money 20% | -0.4 |
| Insiders net selling recently. info | |
| Institutional Flow info | NA |
| Short Interest info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars disagree, so the score is softened. | |
| Not in score | |
| Priced low for its earnings growth. info | |
| Near its medium-term trend line. info | |
| Price is high against its 52-week average. Up over 5 years. info | |
| Trend up on all three terms. Short-term momentum rising. info | |
| Price is between support and resistance. info | |
| Final Score | -0.01 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Jazz Pharmaceuticals plc | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| JAZZ | - | - | - | 3.68 | 0.0 |
| HLVX | 103 M | - | - | 0.710 | 0.0 |
| IPA | 96 M | - | - | 5.98 | -0.5 |
| MEIP | 49 M | - | - | - | 0.0 |
| SONN | 33 M | - | - | 2.07 | -1.4 |
| OMER | - | - | - | - | -1.2 |
Select this tab to load the latest available analysis.
|
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.04% |
| % Held by Institutions | 101.22% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| COZADD BRUCE C | - | 234.76 | -68,808 | -16,153,366 |
| Aggregate Net Quantity | -68,808 | |||
| Aggregate Net Value ($) | -16,153,366 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 234.76 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| COZADD BRUCE C | Director | 06 Nov 2026 | Sell (-) | 68,808 | 234.76 | 16,153,366 |
| COZADD BRUCE C | Director | 06 Nov 2026 | Option execute | 86,500 | - | - |
Recent Signals candle patterns and EMA crosses
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |